ASCO 2025: Bicycle Therapeutics highlights Nectin-4-Targeting BT8009 in bladder cancer
Bicycle Therapeutics plc, a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, announced the poster presentation of two… read more.
